# PharmaMar clinical trials: 50 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials with PharmaMar as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by PharmaMar: 50 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pharmamar

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 24, 2026 | NCT07839819 | Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies | PharmaMar | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839819) |
| June 12, 2026 | NCT07644039 | Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies | PharmaMar | Phase 1/2 | Recruiting | Advanced Malignancies | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644039) |
| October 18, 2023 | NCT06088290 | Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic... | PharmaMar | Phase 3 | Active not recruiting | Leiomyosarcoma | 469 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06088290) |
| May 3, 2023 | NCT05841563 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | PharmaMar | Phase 1 | Recruiting | Advanced Solid Tumor | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05841563) |
| April 28, 2023 | NCT05835609 | PM534 Administered Intravenously to Patients With Advanced Solid Tumors | PharmaMar | Phase 1 | Recruiting | Patients With Advanced Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05835609) |
| January 30, 2023 | NCT05705167 | Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) | PharmaMar | Phase 2 | Terminated | COVID-19 | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05705167) |
| December 10, 2021 | NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed... | PharmaMar | Phase 3 | Completed | Relapsed Small Cell Lung Cancer | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05153239) |
| November 16, 2021 | NCT05121740 | Extension Study in a Cohort of Adult Patients With COVID-19 Infection | PharmaMar | Phase 1/2 | Completed | COVID-19 Infection | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05121740) |
| November 1, 2021 | NCT05101265 | Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment | PharmaMar | Phase 1 | Unknown | Advanced Solid Tumor, Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05101265) |
| October 13, 2021 | NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | PharmaMar | Phase 1 | Completed | Advanced Solid Tumor | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05076396) |
| October 8, 2021 | NCT05072106 | Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors | PharmaMar | Phase 1 | Completed | Advanced Solid Tumor | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05072106) |
| October 1, 2021 | NCT05063318 | Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors | PharmaMar | Phase 1 | Completed | Advanced Solid Tumors | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05063318) |
| March 5, 2021 | NCT04784559 | Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection | PharmaMar | Phase 3 | Terminated | COVID-19 Infection | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04784559) |
| May 11, 2020 | NCT04382066 | Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 | PharmaMar | Phase 1 | Completed | COVID-19 | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04382066) |
| February 9, 2018 | NCT03427268 | Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment | PharmaMar | Phase 2 | Completed | Advanced Colorectal Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03427268) |
| April 17, 2017 | NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to... | PharmaMar | Phase 2 | Terminated | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03117361) |
| March 6, 2017 | NCT03070964 | A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma | PharmaMar | Phase 2 | Terminated | Lymphoma | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03070964) |
| July 7, 2016 | NCT02825420 | Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients | PharmaMar | Observational | Completed | Relapsed Ovarian Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02825420) |
| November 20, 2015 | NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | PharmaMar | Phase 1/2 | Completed | Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma, Epithelial Ovarian... | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02611024) |
| October 2, 2015 | NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | PharmaMar | Phase 3 | Completed | Small-cell Lung Cancer | 613 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02566993) |
| August 27, 2015 | NCT02533674 | Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced... | PharmaMar | Phase 1 | Completed | Solid Tumors | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02533674) |
| May 27, 2015 | NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | PharmaMar | Phase 2 | Completed | Advanced Solid Tumors | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02454972) |
| May 21, 2015 | NCT02451007 | Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors | PharmaMar | Phase 2 | Completed | Solid Tumors | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02451007) |
| April 20, 2015 | NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | PharmaMar | Phase 3 | Completed | Ovarian Cancer | 442 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02421588) |
| August 6, 2014 | NCT02210364 | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC)... | PharmaMar | Phase 1 | Completed | Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02210364) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 1/2 | 5 |
| Phase 2 | 15 |
| Phase 3 | 6 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 34 |
| Terminated | 10 |
| Recruiting | 3 |
| Not yet recruiting | 1 |
| Active not recruiting | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 13 |
| Multiple Myeloma | 4 |
| Lymphoma | 4 |
| COVID-19 | 4 |
| Leukemia | 3 |
| Breast Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Small Cell Lung Carcinoma | 3 |
| Sarcoma | 2 |
| Endometrial Neoplasms | 2 |
| Colorectal Neoplasms | 2 |
| Neuroendocrine Tumors | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Neoplasms, Plasma Cell | 1 |
| Leiomyosarcoma | 1 |
| Uterine Cervical Neoplasms | 1 |
| Glioblastoma | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Mesothelioma | 1 |
| Gastro-enteropancreatic neuroendocrine tumor | 1 |
| Stomach Neoplasms | 1 |
| Primary Myelofibrosis | 1 |
| Pancreatic Neoplasms | 1 |
| Mesothelioma, Malignant | 1 |
| Prostatic Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric orthopedic surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-orthopedic-surgery-practices/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
- [Business consulting firms in the United States](https://specstream.ai/data/businesses/business-consulting-firms/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
- [Moving companies in the United States](https://specstream.ai/data/businesses/moving-companies/united-states)
- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
